Cancer cell proteins and cervical cancer return risk
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial looks at whether certain proteins that stop cell death (called inhibitor of apoptosis proteins) in cervical cancer tissue can help predict if the cancer will come back after treatment. It studies patients who had chemoradiation for advanced cervical cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had chemoradiation as your only treatment for locally advanced cervical cancer (stages 1b to 4b).
- You are 18 years or older.
- You have been followed for at least 2 years after your treatment ended.
- A sample of your cancer taken before treatment is still available for testing.
- You are willing to let the researchers use your medical information and samples.
- You have health insurance.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether HPV infection stays in the body during and after standard radiation treatment for cervical cancer, and if that affects how well the treatment works. It aims to understand more about why some people respond better than others.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This trial uses a special blood test to look for tumor DNA in your blood to monitor for cervical cancer recurrence and help guide treatment decisions. It may help your doctor know if your cancer is coming back and choose the best treatment options.
This study uses a simple blood test to look for tiny bits of cancer DNA after your treatment. It aims to see if this test can help predict whether the cancer might come back.
This Phase 3 study tests whether giving additional (adjuvant) chemotherapy after standard chemoradiation can help people whose blood test still shows cancer-related HPV DNA. It may help by lowering the risk of the cervical cancer coming back in people who have a positive blood biomarker after treatment.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) alongside radiation therapy for people whose cervical cancer has returned or spread to a few other places. The goal is to see if this approach can help control the cancer better and improve survival.
Hear when a new Cancer of Cervix trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.